Supernus Pharmaceutical’s stock declined following the release of disappointing Phase IIb trial results for SPN-820, an ...

After SPN-820's failure, Supernus is relying on its non-stimulant ADHD drug Qelbree and the recently approved Parkinson’s ...

Supernus Pharmaceuticals said on Tuesday its depression treatment trial failed to meet the main goal of reduction in depressive symptoms, sending its shares down 20% aftermarket. The company said the ...

Faster-acting drugs have long been sought to protect people with severe depression who may be at risk of self-harm or suicide ...

Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing to treatment-resistant depression (TRD).

Supernus' SPN-820 Phase 2b study in treatment-resistant depression failed to meet its primary endpoint, prompting further ...

Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, has emerged as an effective therapeutic agent for the management of treatment-resistant depression. Repeated treatments with ...

Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS ...

In the second episode of The Deep End, listeners hear what it’s like to live with severe depression and the backstory of an experimental treatment.

Supernus Pharmaceuticals may have had a potential path forward for its depression drug candidate cut off after the asset ...

The phase IIb study results of Supernus Pharmaceuticals Inc.’s SPN-820 in treatment-resistant depression had pulled the company’s stock (NASDAQ:SUPN) down 15.6% on Feb. 19. The randomized, ...

Cantor Fitzgerald last night downgraded Supernus (SUPN) to Neutral from Overweight with a price target of $36, down from $57. The firm cites ...